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Background: Malaria rapid diagnostic tests (RDTs) are generally considered as point-of-care tests. However, most of
the studies assessing the performance of malaria RDTs are conducted by research teams that are not representative
of the classical end-users, who are typically unskilled in traditional laboratory techniques for diagnosing malaria. To
evaluate the performance of a malaria RDT by end-users in a malaria-endemic area, a study protocol was designed
and the VIKIA® Malaria Ag Pf/Pan test, previously evaluated in 2013, was re-evaluated by representative end-users.
Methods: Twenty end-users with four different profiles in seven communes in Kampot Province (Cambodia) were
selected. A set of 20 calibrated aliquots, including negative samples, low positive samples (200 parasites/μL of
Plasmodium falciparum and Plasmodium vivax) and high positive samples (2,000 parasites/μL of P. falciparum and
P. vivax) was used. Testing was performed directly by the end-users without any practical training on the VIKIA®
Malaria Ag Pf/Pan kit.
Results: All results obtained by the end-users were consistent with the expected results, except for the low positive
(200 parasites/μL) P. vivax aliquot (35% of concordant results). No significant difference was observed between the
different end-users. End-user interviews evaluating ease-of-use and ease-of-reading of the VIKIA® Malaria Ag Pf/Pan
kit recorded 159 positive answers and only one negative answer. Out of 20 end-users, only one considered the test
was not easy to perform with the support of the quick guide.
Conclusions: The data presented in this study clearly demonstrate that the performance of the VIKIA® Malaria Ag
Pf/Pan test when performed by traditional end-users in field conditions is similar to that obtained by a research
team and that this RDT can be considered as a point-of-care tool/assay. Furthermore, the protocol designed for this
study could be used systematically in parallel to conventional evaluation studies to determine the performance of
malaria RDTs in field conditions.
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CambodiaBackground
Malaria remains one of the most important infectious
diseases in tropical area, affecting over 300 million
people every year, mainly in sub-Saharan Africa [1,2]. As
recommended by the World Health Organization (WHO),
the management of suspected malaria cases relies on early
diagnosis and prompt and effective treatment based on
artemisinin-combined therapy (ACT) [3].* Correspondence: dmenard@pasteur-kh.org
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unless otherwise stated.Malaria diagnosis has long been based on the micros-
copy examination of Giemsa-stained blood film, despite
the requirement for highly qualified microscopists and
reliable equipment, which are often lacking in remote
areas where malaria is most prevalent [4]. For over a
decade, the development of malaria rapid diagnostic
tests (RDTs) has enabled reliable biological diagnostic
testing in all situations where previously only clinical
diagnosis was available [5]. The main advantages of the
malaria RDTs are that they are easy to use, do not require
electricity or complex equipment and the results areis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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tion [6]. These lateral flow immunochromatographic tests
are usually presented in various formats (dipstick, plastic
cassette or card). They contain antibodies conjugated to
colloidal gold or latex particles, which bind specifically
with parasite antigens. They are generally based on the
detection of the histidine-rich-2 protein (HRP-2) specific
to Plasmodium falciparum but often combined with the
detection of other antigens common to all species, such as
lactate dehydrogenase or aldolase. These combined RDTs
can detect both P. falciparum and non-P. falciparum
(Plasmodium vivax, Plasmodium ovale and Plasmodium
malariae) infections [7].
Over the past few years, the number of malaria RDTs
and the scale of their use have rapidly increased. With
over 100 commercially produced RDTs, this market has
led to a proliferation in product availability against a
background of relatively low capacity for regulation and
quality control in many low-resourced, malaria-endemicFigure 1 Location of the selected end-users, Kampot Province, Cambcountries. The variable quality of malaria RDTs, and
consequently their diagnostic performance, have made it
difficult for policy makers to determine which tests are
the most suitable [5], even with the implementation of
the lot-testing programme, led by WHO in partnership
with the UNICEF/UNDP/World Bank/WHO Special
Programme for Research and Training in Tropical Dis-
eases (TDR) and the Foundation for Innovative New
Diagnostics (FIND) [8].
At present, malaria RDTs are considered as point-of-
care tests because they are mainly used by health care
volunteers at community level, in remote malaria areas.
Their use in field conditions allows an early diagnosis of
malaria in any febrile patient and prompt treatment of
confirmed cases. However, most of the studies aiming to
assess the performance of malaria RDTs are conducted
by research teams that are not representative of the
classical end-users, who are typically unskilled in trad-
itional laboratory techniques for diagnosing malaria.odia.
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aria RDTs is evaluated and information regarding their
‘global’ performance (including ease of use, execution,
interpretation of results, and adherence to test results)
when they are used by the traditional end-users is lacking.
In this context, a protocol for evaluating the global
performance of malaria RDTs by end-users in malaria-
endemic areas was developed. As an example, the per-
formance of the VIKIA® Malaria Ag Pf/Pan test, previously
assessed in 2013 [9], was re-evaluated by representative
end-users, using well characterized and calibrated blood
samples in several testing sites in Cambodia. Results
obtained by the end-users were compared to the corre-
sponding expected results. In addition, a questionnaire
assessing the ease-of-use of the RDT with the support
of the package insert and the quick guide was also
developed.
Methods
VIKIA® Malaria Ag Pf/Pan test
The VIKIA® Malaria Ag Pf/Pan (IMACCESS/bioMérieux,
Lyon, France) is a test based on immunochromatographic
technology for detecting P. falciparum and other species
of Plasmodium (P. vivax, P. malariae and P. ovale). This
test is a ready-to-use cassette device, requiring the operatorTable 1 List of selected end-users, Kampot Province, Cambod
End-user Location
Village
#1 Health medical centre staff TrapaingVeng
#2 Pharmacist TrapaingVeng
#3 Village malaria worker TrapaingVeng
#4 Physician Taphoul
#5 Pharmacist TrapaingVeng
#6 Health medical centre staff Rokarthmey
#7 Physician Kamnob
#8 Village malaria worker PangTeuk
#9 Pharmacist TrapaingVeng
#10 Physician Mononob
#11 Health medical centre staff TrapaingVeng
#12 Village malaria worker Mononob
#13 Physician Chres
#14 Village malaria worker Thmear
#15 Pharmacist Chres
#16 Health medical centre staff TrapaingVeng
#17 Health medical centre staff PreyYao
#18 Physician PreyYao
#19 Pharmacist PreyYao
#20 Village malaria worker PreyKhmaoto transfer 5 μL of blood in the sample well with an
appropriate device supplied in the kit, add five drops
of the lysis buffer in the buffer well and read the re-
sults visually after 20 minutes (see Additional files 1
and 2; SF1 Quick guide for using the VIKIA® Malaria
Ag Pf/Pan RDT and SF2 Package Insert of the VIKIA®
Malaria Ag Pf/Pan RDT).
Participating communes and end-users
Seven communes in Kampot Province (Cambodia) were
selected for this multisite, blinded study. Four different
end-user profiles were considered as representative of
the typical malaria RDTs end-users found in malaria-
endemic areas: health medical centre staff, private phys-
ician, community health worker (village malaria worker
(VMW)) and private pharmacist. Five individuals of
each end-user profiles were enrolled in the study, as
presented in Figure 1 and Table 1.
Sample characteristics
Three types of sample (negative, low positive, high posi-
tive) were tested in replicates of four, corresponding to a
panel of 20 aliquots, as followed: one negative sample,
one low positive sample at 200 parasites of P. falcip-





Snay Anchit Chumkiri Kampot
TrapaingRaing Chumkiri Kampot
Srae Samraong Chumkiri Kampot
Srae Chaeng Chumkiri Kampot
Srae Chaeng Chumkiri Kampot
TrapaingRaing Chumkiri Kampot
Chumpu Voan Chumkiri Kampot
TrapaingRaing Chumkiri Kampot





Srae Khnong Chumkiri Kampot
Srae Khnong Chumkiri Kampot
Srae Khnong Chumkiri Kampot
Srae Khnong Chumkiri Kampot
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sites of P. falciparum/μL and one high positive sam-
ple at 2,000 parasites of P. vivax/μL.
The set of 20 coded aliquots was prepared according
to the Standard Operating Procedures (SOP) developed
in the Methods Manual for Laboratory QC Testing of
Malaria RDTs (Version 7, June 2014) and codified as
described in Table 2. Briefly, the preparation of positive
parasite samples was performed in three steps: i) blood
sample collection from consenting malaria patients
(strong positive detection by RDT and parasite density >
2,000 parasites/μL of blood by microscopy); ii) collection
of parasite-free (controlled by PCR [10]) and virus-free
(controlled by serological screening for HIV, hepatitis B
and hepatitis C infections) blood from the Phnom Penh
blood bank and, iii) dilution of the parasite-positive bloods
in low (200 parasites/μL) and high (2,000 parasites/μL)
parasite densities and preparation of parasite-negative
QC samples and aliquoting (50 μL) in cryotubes frozen
at −80°C.
Frozen calibrated blood aliquots were transported
at −80°C in a portable freezer running on 12 V (works
with a cigarette lighter in a car). Defrosting was performed
by the research team just before its use by the end-user
(Figure 2).Table 2 List of the set of 20 parasite-calibrated blood
aliquots used by the selected end-users, Kampot Province,
Cambodia
Aliquot ID Plasmodium species Parasite density (/μL)
Aliquot 1 P. vivax 2,000
Aliquot 2 P. vivax 200
Aliquot 3 -
Aliquot 4 P. vivax 200
Aliquot 5 P. falciparum 200
Aliquot 6 P. falciparum 2,000
Aliquot 7 P. vivax 2,000
Aliquot 8 -
Aliquot 9 P. falciparum 200
Aliquot 10 P. vivax 2,000
Aliquot 11 P. falciparum 2,000
Aliquot 12 P. falciparum 200
Aliquot 13 P. falciparum 2,000
Aliquot 14 P. vivax 2,000
Aliquot 15 P. vivax 200
Aliquot 16 P. falciparum 2,000
Aliquot 17 -
Aliquot 18 -
Aliquot 19 P. vivax 200
Aliquot 20 P. falciparum 200Training
Before the start of the study, the research team ex-
plained the study objective to all end-users. Testing was
performed directly by the end-users without any prac-
tical training on the VIKIA® Malaria Ag Pf/Pan kit. The
only instructions for use were available within the quick
guide and the package insert provided in the VIKIA®
Malaria Ag Pf/Pan kit (see Additional files 1 and 2).
Quality control assessment of the calibrated aliquots
The research team performed a quality control assess-
ment of the set of the 20 aliquots at three different times
(at the start, middle and end of the study), to confirm
the good quality of the aliquots distributed to the users
and to verify that no degradation occurred during trans-
port or storage that could affect the expected results.
Statistical analysis
Data were recorded and analysed using Excel software
and MedCalc (MedCalc Software, Belgium). The Chi-
squared test was used to compare the proportion of
positive results among end-users. A P-value <0.05 was
considered to indicate statistical significance.
Results
Quality assessment testing results
Three successive quality assessments were performed
by the research team: firstly in Phnom Penh at Institut
Pasteur in Cambodia before going into the field, secondly
and thirdly, seven and 14 days later, respectively, in the
field. Results are presented in Table 3.
Quality assessments 2 and 3 showed a significant
degradation of the quality of three out of four aliquots
containing P. vivax at 200 parasites/μL. For this reason,
aliquots ID 4, ID15 and ID19 were excluded from the
final analysis of the end-user testing results.
End-user testing results
Among the 20 selected end-users, the results observed
were consistent with the expected results, except for the
low positive (200 parasites/μL) P. vivax aliquot with 35%
of concordant results (Table 4).
No significant difference was observed between the
different end-users. For the low positive (200 parasites/
μL) P. vivax aliquot, the proportion of positive results
obtained by the VMW end-users (80%) was higher than
other end-users (0-40%), but the difference was not sig-
nificant (P = 0.22), and was probably due to the low
number of aliquots tests (five per end-user).
Questionnaire evaluation analysis
After performing the test, all end-users were interviewed
and completed a questionnaire (‘use and usability’) to
evaluate ease-of-use and ease-of-reading of the VIKIA®
Figure 2 Flow chart of the use in field conditions of well-characterized and calibrated blood samples (set of 20 aliquots) by selected
end-users, Kampot Province, Cambodia.
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159 positive answers (yes, 99.4%) and only one negative
answer (no, 0.6%) were recorded.
Out of the 20 end-users, only one considered the test
was not easy to perform with the support of the quick
guide. However, with the help of the package insert, all
end-users considered that the operating instructions
were clear enough to perform the test without having to
participate in practical training. Moreover, all end-users
claimed that the package insert allowed an easy inter-
pretation of the results.
Discussion
In endemic areas, health facility staff and community
workers are in the front line to manage malaria cases,Table 3 Results of the three quality assessments performed b
Aliquot ID QA 1 (Day 0) QA 2 (D
RDT reading results Interpretation RDT rea
C Pf Pan C P
3 Negative P A A Concordant P A
8 Negative P A A Concordant P A
17 Negative P A A Concordant P A
18 Negative P A A Concordant P A
5 P. falciparum - 200 P P A Concordant P P
9 P. falciparum - 200 P P A Concordant P P
12 P. falciparum - 200 P P A Concordant P P
20 P. falciparum - 200 P P A Concordant P P
6 P. falciparum – 2,000 P P P Concordant P P
11 P. falciparum – 2,000 P P P Concordant P P
13 P. falciparum – 2,000 P P P Concordant P P
16 P. falciparum – 2,000 P P P Concordant P P
2 P. vivax - 200 P A Pw Concordant P A
4 P. vivax - 200 P A Pw Concordant P A
15 P. vivax - 200 P A Pw Concordant P A
19 P. vivax - 200 P A Pw Concordant P A
1 P. vivax – 2,000 P A P Concordant P A
7 P. vivax – 2,000 P A P Concordant P A
10 P. vivax – 2,000 P A P Concordant P A
14 P. vivax – 2,000 P A P Concordant P A
QA: quality assessment; C: control line; Pf: P. falciparum line (HRP-2 line detection);
positive weak.which mostly affect rural inhabitants, for achieving the
laudable goal of elimination. To this end, early diagnosis of
malaria by using malaria RDT and prompt treatment with
effective anti-malarial drugs are the cornerstone of the
management of suspect malaria cases [11]. Therefore,
malaria RDTs are one of the most important tools to
ensure that only malaria-infected patients receive anti-
malarial drugs, limiting the unnecessary use of inappropri-
ate treatment and thereby avoiding selection and spread
of drug-resistant P. falciparum parasites, an important
issue in Southeast Asia [12]. According to WHO, most
of the 108 million malaria RDTs delivered in 2012
were used in the African region (78%), followed by the
Southeast Asia region (16%) and Eastern Mediterranean
region (3%) [11].y the research team
ay 7) QA 3 (Day 14)
ding results Interpretation RDT reading results Interpretation
f Pan C Pf Pan
A Concordant P A A Concordant
A Concordant P A A Concordant
A Concordant P A A Concordant
A Concordant P A A Concordant
A Concordant P P A Concordant
A Concordant P P A Concordant
A Concordant P P A Concordant
A Concordant P P A Concordant
P Concordant P P P Concordant
P Concordant P P P Concordant
P Concordant P P P Concordant
P Concordant P P P Concordant
Pw Concordant P A Pw Concordant
A Discordant P A A Discordant
Pw Concordant P A A Discordant
A Discordant P A A Discordant
P Concordant P A P Concordant
P Concordant P A P Concordant
P Concordant P A P Concordant
P Concordant P A P Concordant
Pan: Plasmodium line (aldolase detection line); P: positive; A: negative; Pw:
Table 4 Results of the tests performed by selected end-users
Aliquot status Aliquots used End-users No. of
tests performed
No. of aliquots declared as % of concordant
resultsNegative P. falciparum Non-P. falciparum
Negative ID3, ID8, ID17,
ID18
Health centre staff 20 20 0 0 100%
Pharmacist 20 20 0 0 100%
Village malaria worker 20 20 0 0 100%
Physician 20 20 0 0 100%





Health centre staff 20 0 20 0 100%
Pharmacist 20 0 20 0 100%
Village malaria worker 20 0 20 0 100%
Physician 20 0 20 0 100%





Health centre staff 20 0 20 0 100%
Pharmacist 20 0 20 0 100%
Village malaria worker 20 0 20 0 100%
Physician 20 0 20 0 100%





Health centre staff 20 0 0 20 100%
Pharmacist 20 0 0 20 100%
Village malaria worker 20 0 0 20 100%
Physician 20 0 0 20 100%
All 80 0 0 80 100%
P. vivax -
200 parasites/μL
ID2 Health centre staff 5 5 0 0 0%
Pharmacist 5 4 0 1 20%
Village malaria worker 5 1 0 4 80%
Physician 5 3 0 2 40%
All 20 13 0 7 35%
Table 5 Results of the questionnaire evaluation, Kampot, Cambodia, 2013
Use of the test No. of YES (%) Comments
Are the instructions given in the package insert easily understandable for use by you? 20/20 (100%)
With only the support of the quick guide, is it easy to perform the test? If not,
specify the part or parts which you do not easily understand:
19/20 (95%) Part 3, I consider that one drop is
equal to 5x
Is the test easy to use for someone who is not a trained laboratory technician?
If not, please explain:
20/20 (100%)
Are the operating instructions clear enough to understand the test without having
to participate in practical training?
20/20 (100%)
Is the time to perform the test compatible with its use in the field? If not, give
an estimate of a time that seems to be acceptable, from sampling to result.
20/20 (100%) 1 comment: 15 min will be better
Result interpretation
Do the instructions given in the package insert allow an easy interpretation of
the results? If not, please explain:
20/20 (100%)
With only the support of the quick guide, is the result easy to interpret? 20/20 (100%)
Do you think that reading and result interpretation of the test are easy to read
and interpret for someone who has not trained as a laboratory technician?
If not, please explain:
20/20 (100%)
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formance malaria RDTs in terms of sensitivity, specifi-
city, positive, and negative predictive values is crucial.
However, most of the studies aiming to evaluate the per-
formance of commercialized malaria RDTs are con-
ducted by research teams, that are not representative of
the traditional end-users in remote areas, whereas sev-
eral studies have clearly shown that the accuracy of mal-
aria RDTs is highly user-dependent [13-20]. Indeed, it
has been demonstrated by Rennie et al. that despite their
apparent simplicity of use, the accuracy of malaria RDTs
also depends on the accuracy of their preparation and
interpretation [21]. In most of the studies, data relating
to the quality of packaging and content, ease of use and
ease of interpretation of results from malaria RDTs are
missing [22].
In the present study, a dedicated protocol was de-
signed to re-evaluate the performance of the VIKIA®
Malaria Ag Pf/Pan test, previously assessed in 2013
[9], by representative end-users. To this end, well-
characterized and calibrated blood samples were used,
along with in-depth interviews to assess ease-of-use
and ease-of-reading of the VIKIA® Malaria Ag Pf/Pan
test. Globally, the performance of the VIKIA® Malaria
Ag Pf/Pan test performed by the 20 selected end-users
was consistent with expected results and similar to those
previously observed by Chou et al. [9]. No significant dif-
ference was observed between the different end-users,
including health medical centre staff, private physicians,
community health workers and private pharmacists. With
the instructions provided in the quick guide and the
package insert, most of the end-users considered that
the VIKIA® Malaria Ag Pf/Pan test was easy to use
and the results were easy to interpret.
The results observed with the low positive P. vivax ali-
quot (200 parasites/μL) with a sensitivity of 35% (95%
CI: 15.4-59.2%) were similar to the sensitivity reported
for P. vivax samples containing 101–500 parasitaemia/
μL of blood by Chou et al. (from 36.4 to 61.9%, accord-
ing to the reading time, 10–60 minutes) [9]. In addition,
data from the quality control assessment performed at
three different times (at the start, middle and end of the
study), confirmed that the storage of low parasitaemia
P. vivax samples at low temperatures had probably ac-
celerated the deterioration of antigen activity (among
the 12 low positive P. vivax aliquots, seven were positive
and five were negative) [7]. The 200 parasites/μL density
level was included in the protocol according to the
1999 and 2003 WHO consultations (above the 100
parasites/μL level) [23,24]. The 2010 WHO consult-
ation on parasite detection confirmed the relevance of
this level for clinical management, in high and medium/
low transmission areas [25], taking into account that clin-
ical malaria at low parasite densities occurs in a numberof communities, especially in unstable low transmission
areas.
The main limitations of the study were the limited
number of samples tested, especially the number of low
positive P. vivax aliquots and the use of frozen samples,
although no other option was available. Indeed, it has
been claimed by some RDT manufacturers that frozen
blood samples are not optimum for RDT testing. They
argue that malaria RDTs are optimized and recommended
to be used with fresh finger-prick blood and that frozen
blood samples could lead to aggregation, precipitation and
leeching out of artefacts into the thawed blood. As all
RDTs use a porous nitrocellulose membrane, the presence
of artefacts clogging the membrane can alter the flow
properties of the reagents and affect the completion of the
test run in specified time. As a future option, WHO, TDR
and FIND, along with other partners, have started the
development of a generation of lot-testing samples based
on the use of recombinant proteins, which could be used
by community health workers to confirm quality of RDTs
and significantly increase the confidence of national mal-
aria control programmes in the results of RDTs.
Conclusions
The data presented in this study clearly demonstrate that
the performance of the VIKIA® Malaria AgPf/Pan rapid
test performed by traditional end-users in field condi-
tions is similar to those obtained by a research team,
and that VIKIA® Malaria AgPf/Pan can be considered as
a point-of-care test. In addition, the protocol designed
for this study, using well-characterized and calibrated
blood samples at 2,000 and 200 parasites/μL could be
used systematically in parallel to conventional evaluation
studies [7] to determine the performance of malaria
RDTs in field conditions.
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